MEDIOMICS, LLC

Biotech · Private

Fluorescence-based reagents and assays for site-specific detection and imaging of RNA modifications (m6A, pseudouridine, m5C, and other epitranscriptomic marks) in cells and biological samples

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Total capital: $4.6M

Federal grants: $3.7M; 9 awards · 2016–2025; Rank in peer group#24 of 42
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $887K; 2 awards · Health and Human S; Rank in Biotech#194 of 4373
Granted patents: 4; 5 pending · first 2017; Rank in peer group#10 of 42

Capital timeline

Latest events

Aug 2025Federal grantHealth and Human S · Phase II · Fluorescence-based sequence-specific imaging of RNA modifications$744K
Sep 2024Federal grantHealth and Human S · Phase II · Fluorescence-based sequence-specific imaging of RNA modifications$746K
Jul 2021Federal grantHealth and Human S · Phase II · Developing novel immunoassays specific for thyroid stimulating and TSHblocking autoantibodies$495K
Sep 2020Federal grantHealth and Human S · Phase II · Developing novel immunoassays specific for thyroid stimulating and TSHblocking autoantibodies$500K
Jun 2020Federal grantHealth and Human S · Phase I · Fluorescence-based sequence-specific imaging of RNA modifications$225K
Sep 2017Federal grantHealth and Human S · Phase I · Developing novel immunoassays specific for thyroid stimulating and TSH blocking autoantibodies$224K
Mar 2017Federal grantHealth and Human S · Phase I · Developing specific rapid and cost effective immunoassays for Zika detection$300K

Show 4 earlier federal awards

Mar 2017Federal grantHealth and Human S · Phase I · Developing specific, rapid and cost-effective immunoassays for Zika detection$300K
Aug 2016Federal grantHealth and Human S · Phase I · Development of Recombinant Antibodies for Detection of RNA Modifications at Single Nucleotide Resolution$158K
Sep 2012Federal contractHealth and Human S · Igf::ot::igf SBIR Phase II Pincer Assay$738K
Sep 2011Federal contractHealth and Human S · SBIR Topic 294 Phase 1 - Development Of Glycosylation - Specific Research$149K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 42 peers

Line = median

Biotech · Instrument

Federal grantsBelow median
Granted patents#10 · top 24%
Linked publications#2 · top 5%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 4 granted of 9

Sep 17, 2019GrantedBiosensor For Detecting Multiple Epitopes On A TargetUSPTOUS 10,416,157
Apr 30, 2019GrantedMolecular Biosensors With A Modular DesignUSPTOUS 10,274,484
Oct 24, 2017GrantedMolecular Biosensors Capable Of Signal AmplificationUSPTOUS 9,797,892

Show all 9 patent records

Biosensor For Detecting Multiple Epitopes On A TargetSep 17, 2019 · US 10,416,157Granted
Molecular Biosensors With A Modular DesignApr 30, 2019 · US 10,274,484Granted
Molecular Biosensors Capable Of Signal AmplificationOct 24, 2017 · US 9,797,892Granted
Biosensor For Detecting Multiple Epitopes On A TargetJun 6, 2017 · US 9,671,403Granted
Molecular Biosensors With A Modular DesignApplication PCTUS2015049733Pending
Compositions And Methods For Selecting AptamersApplication PCTUS2012047840Pending
Molecular Biosensors Capable Of Signal AmplificationApplication PCTUS2011024547Pending
Biosensor For Detecting Multiple Epitopes On A TargetApplication PCTUS2009065142Pending
Anti-angiogenesis Methods, Compositions And Uses ThereforApplication PCTUS2002037879Pending

Recent research by its founders

Dietary protein-to-carbohydrate ratio affects the immune performance of black soldier fly larvae challenged with bacterial infection20260 cites
Effects of Soybean- and Cottonseed-Based Diets on Growth Performance and Gut Microbiota of Black Soldier Fly Larvae20260 cites
Holistic oncologic management improves quality of life in driver gene negative advanced NSCLC a latent growth curve modeling study20260 cites

LUCIGEN CORPORATIONSimilar federal contract value in Biotech · $994K in contracts
PAK BIOSOLUTIONS, INC.Similar federal contract value in Biotech · $942K in contracts
IREPROGRAM, LLCSimilar federal contract value in Biotech · $903K in contracts
GENCYTE THERAPEUTICS INCSimilar federal contract value in Biotech · $855K in contracts
NOMOCAN PHARMACEUTICALS LLCSimilar federal contract value in Biotech · $854K in contracts
Nanoscience Solutions, LLCSimilar federal contract value in Biotech · $849K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.